Compare BAER & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAER | CUE |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | 191 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.3M | 124.5M |
| IPO Year | N/A | 2017 |
| Metric | BAER | CUE |
|---|---|---|
| Price | $1.86 | $27.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $120.00 |
| AVG Volume (30 Days) | ★ 789.5K | 70.2K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | $16.47 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $1.47 | $0.17 |
| 52 Week High | $3.44 | $41.42 |
| Indicator | BAER | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 58.24 |
| Support Level | $1.57 | $0.30 |
| Resistance Level | $1.92 | $32.60 |
| Average True Range (ATR) | 0.11 | 3.83 |
| MACD | -0.02 | -0.46 |
| Stochastic Oscillator | 11.11 | 61.52 |
Bridger Aerospace Group Holdings Inc operates as an aerial firefighting company. It provides aerial wildfire surveillance, relief and suppression, and aerial firefighting services using next-generation technology and environmentally friendly and sustainable firefighting methods. Bridger Aerospace provides aerial firefighting and wildfire management services to federal and state government agencies, including the United States Forest Service, across the nation. The company's portfolio is organized across two offerings: Fire Suppression, which Consists of deploying specialized Viking CL-415EAF (Super Scooper) aircraft to drop large amounts of water quickly and directly on wildfires, and Aerial Surveillance, providing aerial surveillance via manned aircraft for fire suppression aircraft.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.